Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06531642 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients

Study acronym: Trauma AKI PPI
StatusRecruiting
PhasePhase 2/3
Started2024-09-07
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 19, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-02-17
minor
Study Identification, Study Status, Contacts/Locations v2
Primary completion date2025-07-31→2026-07-31
Completion date2025-07-31→2026-09-01
Study sitescontacts updated at 1 of 1 site
2024-09-25
notable
Not Yet Recruiting→Recruiting Study Identification, Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-08-01→confirmed 2024-09-07
Study sitesdetails revised at 1 of 1 site
2024-07-25
minor
Original filing
The investigators propose a single-center, randomized, controlled trial to determine whether early initiation of proton pump inhibitor (PPI), pantoprazole, will decrease acute kidney injury (AKI) for trauma patients presenting with hemorrhagic shock compared to routine timing of initiation of PPI. Kidney injury will be assessed by the urinary kidney injury biomarkers, and the incidence, severity and AKI-free days within first week and major adverse kidney events (MAKE) at day 30. The specific aims of the study will be achieved by a cohort of 100 patients to receive either early(study) or routine (control) administration of pantoprazole for 2 days after the initial injury insult.
Trial Details
NCT Number NCT06531642
Lead Sponsor The University of Texas Health Science Center, Houston
Collaborators: The University of Texas Health Science Center at San Antonio
Conditions Acute Kidney Injury
Enrollment 100 participants
Start Date 2024-09-07
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-19